hiv core protein p24

Summary

Summary: A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.

Top Publications

  1. ncbi Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Gloriastr 30, CH 8028 Zurich Switzerland
    AIDS Rev 4:83-92. 2002
  2. pmc Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1
    Javier Martinez-Picado
    IrsiCaixa Foundation, University Hospital Germans Trias i Pujol, Barcelona, Spain
    J Virol 80:3617-23. 2006
  3. pmc Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses
    A D Kelleher
    Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom
    J Exp Med 193:375-86. 2001
  4. pmc Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control
    Rosario Zuniga
    Asociacion Civil Impacta Salud y Educacion, Lima, Peru
    J Virol 80:3122-5. 2006
  5. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
  6. ncbi Structure of the amino-terminal core domain of the HIV-1 capsid protein
    R K Gitti
    Howard Hughes Medical Institute and Department of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, MD 21228, USA
    Science 273:231-5. 1996
  7. pmc Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity
    Samir Abdurahman
    Division of Clinical Microbiology, Karolinska Institutet, F68 Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Antimicrob Agents Chemother 52:3737-44. 2008
  8. pmc The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro
    Shay Matalon
    Department of Medicine, University of Colorado Denver, 12700 E 19th Avenue B 168, Aurora, CO 80045, USA
    J Acquir Immune Defic Syndr 54:1-9. 2010
  9. ncbi Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard
    Marcel Miedouge
    Laboratoire de Virologie, Institut Fédératif de Biologie de Purpan, 330 avenue de Grande Bretagne, TSA 40031, 31059 Toulouse, Cedex 9, France
    J Clin Virol 50:57-60. 2011
  10. pmc Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc
    Yuzhe Yuan
    Transfusion Transmitted Diseases Center, Institute of Blood Transfusion, Chinese Academy of Medical Science, Chenghua District, Chengdu, Sichuan Province, PR China
    PLoS ONE 8:e65115. 2013

Detail Information

Publications203 found, 100 shown here

  1. ncbi Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Gloriastr 30, CH 8028 Zurich Switzerland
    AIDS Rev 4:83-92. 2002
    ..There is no problem with sample instability and no need for cumbersome nucleic acid extraction. The test is validated for subtype B, but requires further studies for non-B subtypes...
  2. pmc Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1
    Javier Martinez-Picado
    IrsiCaixa Foundation, University Hospital Germans Trias i Pujol, Barcelona, Spain
    J Virol 80:3617-23. 2006
    ....
  3. pmc Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses
    A D Kelleher
    Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom
    J Exp Med 193:375-86. 2001
    ..Outgrowth of CTL escape viruses required high viral loads and additional, possibly compensatory, mutations in the gag protein...
  4. pmc Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control
    Rosario Zuniga
    Asociacion Civil Impacta Salud y Educacion, Lima, Peru
    J Virol 80:3122-5. 2006
    ..Analyses in a second cohort in the United States confirm these findings and point towards a dominant role of Gag-specific immunity in effective control of HIV infection, providing important guidance for HIV vaccine development...
  5. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays...
  6. ncbi Structure of the amino-terminal core domain of the HIV-1 capsid protein
    R K Gitti
    Howard Hughes Medical Institute and Department of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, MD 21228, USA
    Science 273:231-5. 1996
    ..In the free monomeric domain, Pro90 adopts kinetically trapped cis and trans conformations, raising the possibility that cyclophilin A catalyzes interconversion of the cis- and trans-Pro90 loop structures...
  7. pmc Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity
    Samir Abdurahman
    Division of Clinical Microbiology, Karolinska Institutet, F68 Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Antimicrob Agents Chemother 52:3737-44. 2008
    ..As an antiviral compound, alpha-HGA has an unusually simple structure, a pronounced antiviral specificity, and a novel mechanism of antiviral action. As such, it might prove to be a lead compound for a new class of anti-HIV substances...
  8. pmc The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro
    Shay Matalon
    Department of Medicine, University of Colorado Denver, 12700 E 19th Avenue B 168, Aurora, CO 80045, USA
    J Acquir Immune Defic Syndr 54:1-9. 2010
    ..Here we compared the efficacy of ITF2357, an orally active and safe HDAC inhibitor, with VPA for HIV-1 expression from latently infected cells in vitro. We also evaluated the effect of ITF2357 on the surface expression of CXCR4 and CCR5...
  9. ncbi Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard
    Marcel Miedouge
    Laboratoire de Virologie, Institut Fédératif de Biologie de Purpan, 330 avenue de Grande Bretagne, TSA 40031, 31059 Toulouse, Cedex 9, France
    J Clin Virol 50:57-60. 2011
    ....
  10. pmc Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc
    Yuzhe Yuan
    Transfusion Transmitted Diseases Center, Institute of Blood Transfusion, Chinese Academy of Medical Science, Chenghua District, Chengdu, Sichuan Province, PR China
    PLoS ONE 8:e65115. 2013
    ..These results suggest that the HIV-1 gp120 V3 mutations that confer maraviroc resistance alter structure and dynamics of the V3 loop on the gp120 outer domain, and enable interactions between gp120 and the drug-bound form of CCR5...
  11. ncbi Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57
    Geraldine M A Gillespie
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK
    AIDS 16:961-72. 2002
    ....
  12. pmc The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell escape mutations and covarying HLA-independent polymorphisms
    Hayley Crawford
    Department of Paediatrics, University of Oxford, Peter Medawar Building for Pathogen Research, South Parks Rd, Oxford OX1 3SY, United Kingdom
    J Virol 85:1384-90. 2011
    ..Our results demonstrate complex patterns of adaptation of HIV under immune selection pressure, the understanding of which should aid vaccine design...
  13. pmc IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines
    Kaustuv Banerjee
    Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, USA
    AIDS Res Hum Retroviruses 26:445-58. 2010
    ..Although we found isotypic differences in IgG responses to HIV-1 antigens among vaccinees and the HC and CP individuals, there were no indications of differential T(H)1:T(H)2 polarization between the different groups...
  14. pmc NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery
    Ari S Nowacek
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 5880, USA
    Nanomedicine (Lond) 4:903-17. 2009
    ..In attempts to bypass such limitations, nanoparticles containing ritonavir, indinavir and efavirenz (described as nanoART) were manufactured to assess macrophage-based drug delivery...
  15. pmc Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes
    Liguo Niu
    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, 1580 NW 10th Ave, Miami, FL, USA
    Vaccine 29:2110-9. 2011
    ..In addition, little is known regarding whether specific HIV-1 proteome components, such as highly conserved regions of the HIV-1, could enhance clinical responses following DC therapy...
  16. pmc A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA
    Ruifeng Yang
    Department of Microbiology and Immunology, Vanderbilt University School of Medicine, A 5301 Medical Center North, Nashville, TN 37232 2363, USA
    J Virol 81:3749-56. 2007
    ..A105T rescued the impaired single-cycle infectivity and replication defects of both T54A and A92E mutants. These results indicate that CA determinants outside the CypA-binding loop can modulate the dependence of HIV-1 infection on CypA...
  17. pmc HIV-1 variation diminishes CD4 T lymphocyte recognition
    G C Harcourt
    Molecular Immunology Group, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 9DU, United Kingdom
    J Exp Med 188:1785-93. 1998
    ..In HIV-1 infection, naturally occurring HLA class II-restricted altered peptide ligands that fail to stimulate the circulating T lymphocyte repertoire may curtail helper responses at sites where variant viruses predominate...
  18. ncbi Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa
    D Bonard
    Centre de Diagnostic et de Recherches sur le SIDA, CHU de Treichville, BP V3 Abidjan, Cote d Ivoire, West Africa
    J Acquir Immune Defic Syndr 34:267-73. 2003
    ..Follow-up of infected patients using both markers showed different results. The reliability of the HD p24 Ag assay is questionable for clinical and biologic management as a surrogate tool for measurement of HIV-1 RNA levels in Africa...
  19. ncbi Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays
    Jung Ah Kwon
    Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Republic of Korea
    J Virol Methods 133:20-6. 2006
    ..0% to 99.6%. The Architect HIV Ag/Ab Combo exhibited the best performance for specificity and detection of p24 antigen leading to closure of seroconversion window and demonstrating its utility for early diagnosis of HIV infection...
  20. ncbi Performance evaluation of the ADVIA Centaur(®) HIV Ag/Ab Combo assay
    Tomas Pumarola
    University of Barcelona Fundacion Clinic, Barcelona, Spain
    J Virol Methods 170:16-20. 2010
    ..74% (7753/7773; 95% confidence interval: 99.60-99.84%). Sensitivity was 100% for the HIV genotypes tested. The HIV Ag/Ab Combo assay is a sensitive and specific assay that can assist clinicians in the early diagnosis of HIV infection...
  21. ncbi Performances of four fourth-generation human immunodeficiency virus-1 screening assays
    Eun Young Song
    Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Med Virol 84:1884-8. 2012
    ..ARCHITECT HIV Ag/Ab Combo and Elecsys HIV Combi PT have the higher analytical sensitivities, and would be preferable for reducing the window period...
  22. pmc A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24
    Angelique Biancotto
    Section on Intercellular Interactions, Program in Physical Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
    J Virol Methods 157:98-101. 2009
    ..This cytometric bead assay allows the detection of p24 concentrations over 4 orders of magnitude from less than 0.4pg to up to 20,000pgml(-1) in a volume of 50microl and can be combined with other measurements...
  23. ncbi High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function
    S Kostense
    Department of Clinical Viro Immunology, CLB Sanquin Blood Supply Foundation and Laboratory for Clinical and Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands
    Eur J Immunol 31:677-86. 2001
    ....
  24. ncbi Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi
    B Weber
    Universitatskliniken Frankfurt Main, Institut für Med Virologie, Zentrum f Hygiene Frankfurt Main, Germany
    Clin Lab 52:463-73. 2006
    ....
  25. pmc Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra
    Bernard Weber
    Laboratoires Réunis Kutter Lieners Hastert, Junglinster, Luxembourg, Germany
    J Clin Microbiol 40:1420-6. 2002
    ..The specificity after initial and/or repeated testing of VIDAS HIV DUO Ultra was equivalent to that of a third-generation assay...
  26. ncbi The effect of capsid mutations on HIV-1 uncoating
    Pathawut Wacharapornin
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    Virology 358:48-54. 2007
    ..Our data indicated that mutations at phosphoacceptor sites of capsid disturbed the uncoating mechanism, but the defect may not be directly caused by the lack of phosphate on the core particles undergoing uncoating...
  27. pmc Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis
    Janet C Patton
    Wits Paediatric HIV Unit, Wits Health Consortium, University of the Witwatersrand, 7 York Rd, Parktown 2193, Johannesburg, South Africa
    Clin Vaccine Immunol 13:152-5. 2006
    ..1 filter paper. The modified assay was found to be reliable and accurate, making it an affordable tool for pediatric HIV diagnosis in developing countries...
  28. ncbi HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia
    John R Koeppe
    Division of Infectious Diseases and Clinical Immunology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 41:140-8. 2006
    ..To determine whether increased sequence variation occurs in regions of endogenous HIV-1 targeted by HIV-1-specific CD4 T cells. The presence of increased variation would be suggestive of immune evasion by HIV-1...
  29. ncbi HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters
    Makoto Sugaya
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, and Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    J Immunol 172:2219-24. 2004
    ..Disrupting cluster formation between LC and memory CD4(+) T cells may be a novel strategy to interfere with sexual transmission of HIV...
  30. pmc Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences
    Gunter Kraus
    Department of Microbiology, University of Miami, 1550 NW 10th Avenue R 138, Miami, FL 33136, USA
    Proc Natl Acad Sci U S A 99:3406-11. 2002
    ..Viral replication and cytopathology associated with infection of multiple HIV-1 clades can be effectively inhibited in CD4(+) cells expressing the RNase P-associated U5 EGS (560) molecule...
  31. pmc Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen
    Shixing Tang
    Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Infect Dis 201:S59-64. 2010
    ..5 pg/mL. These results indicate that the universal labeling technology based on NPs and its application may provide a rapid and sensitive testing platform for clinical diagnosis and laboratory research...
  32. pmc High level soluble expression, one-step purification and characterization of HIV-1 p24 protein
    Baozhong Zhang
    State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
    Virol J 8:316. 2011
    ..The aim of this study was to express and purify the p24 protein in soluble form in E.coli...
  33. ncbi Production of the p24 capsid protein from HIV-1 subtype C in Arabidopsis thaliana and Daucus carota using an endoplasmic reticulum-directing SEKDEL sequence in protein expression constructs
    Ingrid Lindh
    Orebro Life Science Center, Orebro University, Orebro, Sweden
    Protein Expr Purif 66:46-51. 2009
    ..However, on a total soluble protein basis, carrots produced considerable higher levels of the p24_SEKDEL protein than Arabidopsis...
  34. pmc Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity
    Bernard Weber
    Laboratoires Réunis Kutter Lieners Hastert, Junglinster, Luxembourg
    J Clin Microbiol 40:1938-46. 2002
    ....
  35. pmc Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients
    Hayley Crawford
    Department of Pediatrics, University of Oxford, England, UK
    J Exp Med 206:909-21. 2009
    ..These data underline the need for a CTL vaccine against multiple conserved epitopes...
  36. pmc Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection
    T D Ly
    Laboratoire Claude Levy, Ivry sur Seine, France
    J Clin Microbiol 39:3122-8. 2001
    ..Among the combination assays, the AxSYM assay had the best performance for detection of early seroconversion samples, followed by the Murex and VIDAS HIV Duo Ultra assays...
  37. pmc Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid
    Shibani Bhattacharya
    New York Structural Biology Center, New York, New York 10027, USA
    J Biol Chem 283:16274-8. 2008
    ..The results of the structural analysis provide valuable insight into the determinants for high affinity and selective inhibitors for HIV-1 particle assembly...
  38. ncbi Performance evaluation of the new fully automated human immunodeficiency virus antigen-antibody combination assay designed for blood screening
    Eva Sickinger
    Abbott GmbH and Co KG, Wiesbaden, Germany
    Transfusion 48:584-93. 2008
    ..Owing to the capability to detect the early appearance of p24 antigen, combination assays that are designed for simultaneous detection of antibodies and antigen can significantly reduce the diagnostic window...
  39. pmc Combination assay detecting both human immunodeficiency virus (HIV) p24 antigen and anti-HIV antibodies opens a second diagnostic window
    David Speers
    Division of Clinical Microbiology and Infectious Diseases, The Western Australian Centre for Pathology and Medical Research PathCentre, Hospital Avenue, Nedlands, Western Australia 6009, Australia
    J Clin Microbiol 43:5397-9. 2005
    ..Although it is likely to be rare, this phenomenon has also been reported for other fourth-generation HIV immunoassays and has implications for the reported diagnostic windows of these assays...
  40. ncbi Construction and characterization of a recombinant fowlpox virus containing HIV-1 multi-epitope-p24 chimeric gene in mice
    Lishu Zhang
    The 11th Institute, Academy of Military Medical Sciences, Changchun 130062, China
    Sci China C Life Sci 50:212-20. 2007
    ..We concluded that the rFPV may induce HIV-1 specific immunity especially cellular immunity in mice...
  41. ncbi Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals
    Sergio García Ribas
    Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
    J Virol Methods 113:29-34. 2003
    ....
  42. pmc Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method
    Eun Young Kim
    Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, 676 North St Clair, Chicago, IL 60611, USA
    Nanomedicine (Lond) 3:293-303. 2008
    ..We evaluated the efficacy of this protein-detection method in detecting HIV-1 in men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS)...
  43. pmc Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection
    Shixing Tang
    Lab of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 17:1244-51. 2010
    ..The data provide the foundation for development and refinement of new assays for improved p24 antigen testing as future tools for rapid and accurate diagnosis as part of early intervention strategies and estimations of incidence...
  44. ncbi The risk of a second diagnostic window with 4th generation HIV assays: Two cases
    C Niederhauser
    Blood Transfusion Service SRC Berne, Murtenstrasse 133, 3008 Berne, Switzerland
    J Clin Virol 45:367-9. 2009
    ..Despite the improved sensitivity of the 4th generation combined antigen/antibody HIV assays, detection of HIV in the early phase of an infection may still be ineffective...
  45. pmc Production and purification of immunologically active core protein p24 from HIV-1 fused to ricin toxin B subunit in E. coli
    Alberto J Donayre-Torres
    Centro de Investigación y de Estudios Avanzados Cinvestav, Unidad Irapuato, Km 9 6 Libramiento Norte, 36500 Carretera Irapuato León, Irapuato, Guanajuato, Mexico
    Virol J 6:17. 2009
    ..The aim of this study was to investigate the adjuvant-carrier properties of the B ricin subunit (RTB) when fused to p24...
  46. ncbi Transcriptional repression of human immunodeficiency virus type 1 by AP-4
    Kenichi Imai
    Department of Molecular and Cellular Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya, Aichi 467 8601, Japan
    J Biol Chem 281:12495-505. 2006
    ....
  47. pmc Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings
    Richard A Respess
    Global AIDS Program, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mail stop A 12, Atlanta, GA 30333, USA
    J Clin Microbiol 43:506-8. 2005
    ..4% at a viral load of <30,000 (232 specimens from 65 seropositive subjects). The assay was highly reproducible, with excellent correlation between duplicates and among three laboratories...
  48. ncbi Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen
    Janet M Barletta
    Pathology Department, University of Maryland, Baltimore 21201, USA
    Am J Clin Pathol 122:20-7. 2004
    ..IPCR shows the potential to become the most analytically sensitive test available for determination of HIV-1 viral load by the detection of HIV-1 p24 antigen...
  49. pmc Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays
    B Weber
    Laboratoires Réunis Kutter Lieners Hastert, Junglinster, Luxembourg
    J Clin Microbiol 36:2235-9. 1998
    ....
  50. pmc p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection
    Ruengpung Sutthent
    Departments of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    J Clin Microbiol 41:1016-22. 2003
    ..The overall results from this study might renew interest in p24 antigen detection as an easily affordable alternative method for diagnosis of HIV-1 infection and monitoring of disease progression in developing countries...
  51. pmc Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay
    Cheryl Jennings
    Rush Medical College, Department of Immunology Microbiology, 1653 W Congress Parkway, Chicago, IL 60612, USA
    J Clin Microbiol 43:5950-6. 2005
    ..67, and r = 0.59 to 0.95, respectively). Thus, the use of these two assays for monitoring patients, together with less-frequent confirmation testing, offers a feasible alternative to frequent HIV RNA testing in resource-limited settings...
  52. pmc Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay
    Alvaro Pascual
    Department of Microbiology, Universidad de Sevilla, Seville, Spain
    J Clin Microbiol 40:2472-5. 2002
    ..HIV subtypes A to F were all recognized. This assay should be useful for monitoring patients in resource-poor countries and for monitoring vaccine recipients...
  53. pmc Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function
    Meika Richmond
    Department of Medical Microbiology, University of Manitoba, H3440 1015 Arlington St, Winnipeg, MB R3E 3R2 Canada
    J Virol 85:1275-86. 2011
    ..Furthermore, the identification of epitopes that elicit polyfunctional responses reinforces the need for the comprehensive evaluation of HIV vaccine candidates, and these epitopes may represent novel targets for CMI-based vaccines...
  54. ncbi Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 132:196-209. 2003
    ..p24 antigen is an excellent marker of HIV expression and disease activity and can be used in the same fields of application as HIV RNA is used. The test is validated for subtype B, but requires further studies for non-B subtypes...
  55. ncbi In vitro study on vertical transmission of the HIV-1 gag gene by human sperm
    Dian Wang
    Research Center for Reproductive Medicine, Shantou University Medical College, Shantou, China
    J Med Virol 83:16-23. 2011
    ..The results provide evidence for possible vertical transmission of the HIV-1 gag gene to the embryo by fertilizing sperm in vitro...
  56. pmc Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions
    Julia G Prado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Clin Microbiol 42:1620-5. 2004
    ....
  57. ncbi HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection
    James K Coleman
    Department of Pathobiology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32611, USA
    AIDS 19:1457-66. 2005
    ..Based on previous analysis of feline immunodeficiency virus (FIV)-specific cross-reactive antibodies to HIV-1 p24, cats vaccinated with HIV-1 p24 were evaluated for cross-reactive immunity to FIV...
  58. ncbi HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  59. pmc Intracellular HIV-1 Gag localization is impaired by mutations in the nucleocapsid zinc fingers
    Boyan Grigorov
    LaboRetro, Unité de Virologie Humaine INSERM U758, IFR128, ENS, Lyon, France
    Retrovirology 4:54. 2007
    ..In fact, NC controls proviral DNA synthesis by reverse transcriptase (RT), gRNA dimerization and packaging, and virion assembly...
  60. ncbi Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil
    Priscilla Swanson
    Abbott Laboratories, AIDS Research and Retrovirus Discovery, Abbott Park, IL 60064, USA
    J Virol Methods 134:237-43. 2006
    ..5 log(10)copies/ml. The RealTime HIV-1 assay and m2000 system offer the advantages of automation while providing reliable quantification of diverse HIV strains...
  61. pmc Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1
    Charles T T Edwards
    Nuffield Department of Clinical Medicine, University of Oxford, The Peter Medawar Building for Pathogen Research, Oxford, OX1 3SY, UK
    BMC Evol Biol 6:28. 2006
    ..Despite this, the magnitude of this population bottleneck is unclear...
  62. ncbi Centrifugation improves the detection of HIV-1 p24 antigen in plasma from children born to mothers infected with HIV-1
    Maria Sol Dos Ramos Farias
    Centro Nacional de Referencia para el SIDA, Departamento de Microbiologia, Parasitologia e Inmunologia, Facultad de Medicina, Universidad de Buenos Aires, Paraguay, Buenos Aires, Argentina
    J Virol Methods 158:6-10. 2009
    ..Plasma samples with volumes of 1 ml or more achieved a higher sensitivity (91.7% vs. 36.4%, p=0.009). Centrifugation of plasma samples prior to determination of p24 in pediatric patients resulted in a significant increase in sensitivity...
  63. ncbi Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays?
    Thoai Duong Ly
    Laboratoire L C L Claude Lévy, Ivry sur Seine, Paris, France
    J Virol Methods 143:86-94. 2007
    ....
  64. pmc Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa
    G Stevens
    Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand Medical School, Faculty of Health Science and the NHLS, Johannesburg 2193, South Africa
    J Clin Microbiol 43:857-61. 2005
    ..However, both assays provide a less expensive alternative to the Roche viral load assay and demonstrate the same trends during treatment...
  65. ncbi HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 33:292-9. 2003
    ..Comparison of p24 antigen and HIV-1 RNA concentrations indicate that the p24 antigen detected in these samples is not associated with viral RNA-containing particles and may originate from other compartments of virus expression...
  66. ncbi Human immunodeficiency virus type-1 p24 sequence from an Indian strain: expression in Escherichia coli and implications in diagnostics
    S K Gupta
    Gamete Antigen Laboratory, National Institute of Immunology, New Delhi, India
    Gene 190:27-30. 1997
    ..It showed an approx. 24-kDa band by SDS-PAGE. The recombinant p24 reacted with serum samples from HIV-infected subjects when tested by Western blot and ELISA...
  67. ncbi Expression, purification, and characterization of an anti-RBCFab-p24 fusion protein for hemagglutination-based rapid detection of antibodies to HIV in whole blood
    Amita Gupta
    Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, 110 021, New Delhi, India
    Protein Expr Purif 26:162-70. 2002
    ....
  68. ncbi Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 424 N Bond Street, Rm 117, Baltimore, MD 21231, USA
    J Infect Dis 186:1181-5. 2002
    ..Heat-denatured p24 antigen level predicted subsequent clinical disease progression in early-stage HIV-1 infection and correlated with both CD4(+) lymphocyte count and HIV-1 RNA level...
  69. pmc Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
    J M Binley
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2799-809. 1997
    ....
  70. pmc Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication
    B E Palmer
    Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Virol 76:5925-36. 2002
    ....
  71. ncbi A novel and innovative quantitative kinetic software for virological colorimetric assays
    M Giacomini
    Molecular Virology Unit, Advanced Biotechnology Center, Genova, Italy
    J Virol Methods 73:201-9. 1998
    ..The necessity for a wide quantification range has been demonstrated by measuring clinical samples, which showed a distribution in all possible quantification ranges for all kits...
  72. ncbi Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA
    T R Reddy
    Department of Medicine, University of California, San Diego, La Jolla 92093 0665, USA
    Oncogene 19:3570-5. 2000
    ..it is likely that this constitutive export pathway is also used by cellular mRNA, but at a different interface with the splicing process...
  73. ncbi Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians
    Jeffrey R Currier
    The U S Military HIV Research Program, Rockville, Maryland 20850, USA
    AIDS Res Hum Retroviruses 21:239-45. 2005
    ..Efforts to optimize the cross-reactivity of vaccine-induced CD8 T cells may need to focus on the relative immunogenicity of minor sequence variation...
  74. ncbi The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1
    Anthony Pajot
    Unité d Immunité Cellulaire Antivirale, Departement d Immunologie, Institut Pasteur, Paris, France
    Eur J Immunol 37:2635-44. 2007
    ..A T helper effect was demonstrated in all cases, and was particularly strong with epitopes Gag(301-320),Gag(321-340 )and Gag(271-290), which should, therefore, be considered in the design of new vaccines...
  75. ncbi Preserved antigenicity of HIV-1 p24 produced and purified in high yields from plants inoculated with a tobacco mosaic virus (TMV)-derived vector
    D M Pérez-Filgueira
    School of Biological Sciences, University of Nebraska, Lincoln, NE 68588 0118, USA
    J Virol Methods 121:201-8. 2004
    ....
  76. ncbi HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells
    Jacob Nattermann
    Department of Internal Medicine I, Rheinische Friedrich Wilhelms Universitat, Bonn, Germany
    Antivir Ther 10:95-107. 2005
    ..These results propose HIV-mediated up-regulation of HLA-E expression as an additional evasion strategy targeting the antiviral activities of NK cells, which may contribute to the capability of the virus in establishing chronic infection...
  77. pmc Pediatric human immunodeficiency virus screening in an African district hospital
    A J De Baets
    Nutrition and Child Health Unit, Institute of Tropical Medicine, Nationalestraat 155, B 2000 Antwerp, Belgium
    Clin Diagn Lab Immunol 12:86-92. 2005
    ..The results of this study point towards underutilized opportunities to simplify phlebotomy and pediatric HIV screening...
  78. ncbi Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization
    Anne Marte B Kran
    Department of Infectious Diseases, Faculty Division Ullevaal University Hospital, University of Oslo, Kirkeveien 166, NO 0407 Oslo, Norway
    Vaccine 23:4011-5. 2005
    ..04). CD4+ lymphocyte counts were maintained only among DTH high responders but decreased in the other patients during recurrent viremia (p</=0.02). No other pre-study differences in HIV history or p24-responses were found...
  79. pmc CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate
    Jinglin Sun
    Albert Einstein College of Medicine, Forschheimer Building, Room 408, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    J Virol 80:1850-62. 2006
    ..Therefore, the JR-CSF/hu-cycT1 mice should provide an improved mouse system for investigating the pathogenesis of various aspects of HIV-1-mediated disease and the efficacies of therapeutic interventions...
  80. ncbi Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa
    Jean Pierre Lombart
    Hôpital Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso
    AIDS 19:1273-7. 2005
    ..In resource-limited settings, the requirement for inexpensive, easy-to-perform viral load monitoring has increased with greater antiretroviral drug availability...
  81. ncbi HIV insertions within and proximal to host cell genes are a common finding in tissues containing high levels of HIV DNA and macrophage-associated p24 antigen expression
    K D Mack
    SLIL Biomedical Corporation, Menlo Park, California, USA
    J Acquir Immune Defic Syndr 33:308-20. 2003
    ..In certain cases, provirus insertions may mediate the dysregulation of specific gene expression events, providing mechanisms contributing to the pathogenesis associated with certain AIDS-related diseases...
  82. doi The requirement of the DEAD-box protein DDX24 for the packaging of human immunodeficiency virus type 1 RNA
    Jing Ma
    Virology 375:253-64. 2008
    ..We propose that DDX24 acts at the early phase of HIV-1 RNA metabolism prior to nuclear export and the consequence of this action extends to the viral RNA packaging stage during virus assembly...
  83. ncbi Production of HIV-1 p24 protein in transgenic tobacco plants
    G Gary Zhang
    Department of Biology, York University, Toronto, Ontario, Canada
    Mol Biotechnol 20:131-6. 2002
    ..Our results indicate that plant-based transgenic expression represents a viable means of producing p24 for the development of HIV vaccine and for use in HIV diagnostic procedures...
  84. ncbi An HIV seroconversion case: unequal performance of combined antigen/antibodies assays
    Benoît Kabamba Mukadi
    AIDS 16:127-8. 2002
  85. ncbi Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection
    Gayle G Sherman
    Department of Molecular Medicine and Haematology, National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa
    Pediatr Infect Dis J 23:173-6. 2004
    ..A sensitivity of 98.1% and specificity of 98.7% was obtained testing 203 samples from 24 HIV-infected and 66 uninfected infants born to HIV subtype C-infected women...
  86. ncbi Structures of three HIV-1 HLA-B*5703-peptide complexes and identification of related HLAs potentially associated with long-term nonprogression
    Guillaume B E Stewart-Jones
    Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 175:2459-68. 2005
    ....
  87. pmc In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune)
    R B Moss
    The Immune Response Corporation, Carlsbad, California 92008, USA
    Clin Diagn Lab Immunol 5:308-12. 1998
    ..The ability to upregulate immune responses to the more conserved core proteins may have important implications in the development of immunotherapeutic interventions for HIV-1 infection...
  88. pmc Detection and quantification of human immunodeficiency virus type 1 p24 antigen in dried whole blood and plasma on filter paper stored under various conditions
    Chung Chen Li
    Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    J Clin Microbiol 43:3901-5. 2005
    ..These results suggest that transport and storage of plasma on filter paper and quantification of HD p24 Ag may be a reliable method for HIV-1 load monitoring...
  89. ncbi Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings
    Marlyse C Knuchel
    Swiss National Center for Retroviruses, University of Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    J Clin Virol 36:64-7. 2006
    ..Since antiretroviral therapies are becoming more accessible in resource-constrained countries, methods to assess HIV-1 viraemia are urgently needed to achieve a high standard of care in HIV-1 management...
  90. ncbi Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection
    D Nadal
    Pediatric Infectious Diseases Unit, Universitäts Kinderklinik, CH 8032 Zurich, Switzerland
    J Infect Dis 180:1089-95. 1999
    ..002). Variation of RNA concentrations was more marked than that of p24 antigen (P=.002). The p24 antigen test was equivalent to PCR for diagnosing and monitoring pediatric HIV-1 infection...
  91. ncbi Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years
    Lynn S Zijenah
    Department of Immunology, Division of Infectious Diseases, College of Health Sciences, University of Zimbabwe, Harare
    J Acquir Immune Defic Syndr 39:391-4. 2005
    ..These evaluated parameters were not statistically different between infants aged 0-6 and 7-18 months. The ultrasensitive p24 antigen assay is a useful diagnostic test for detection of HIV-1 infection among infants aged 0-18 months...
  92. ncbi Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA
    J Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 65:225-32. 2001
    ..5% of those for RNA (P <.0001). These results indicate that heat-denatured, amplification-boosted p24 antigen measurement can be used as a simple and inexpensive alternative to HIV RNA testing for monitoring treatment...
  93. ncbi Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations
    P Gluschankof
    Centre d immunologie de Marseille Luminy, France
    Virology 230:125-33. 1997
    ....
  94. ncbi Construction and characterization of a full-length infectious molecular clone from the HIV type 1 subtype Thai-B isolated in Henan province, China
    Zheng Wang
    Department of HIV AIDS Research, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
    AIDS Res Hum Retroviruses 24:251-7. 2008
    ....
  95. pmc Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection
    Natalie N Zheng
    Department of Pathology, University of Washington, Seattle, WA 98195, USA
    J Virol 81:9061-71. 2007
    ..In conclusion, the T-cell memory responses associated with containment of single HIV-1 and HIV-2 infection play a similar significant role in the immune control of dual HIV-1 and HIV-2 infection...
  96. ncbi Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study
    D Emilie
    , , Institut Paris-Sud sur les Cytokines, Clamart, France
    AIDS 15:1435-7. 2001
    ..Tolerance was good, and this regimen allowed the early control of HIV replication and rapid decay of the viral reservoir. These results support the initiation of comparative studies with pegylated INF alpha in primary HIV infection...
  97. ncbi Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals
    S Ehrhard
    Institute for Medical Microbiology, University of Basel, Basel, Switzerland
    Infection 36:120-9. 2008
    ..The objective of this study was to investigate the effect of antiretroviral therapy on the lymph node tissue, particularly with respect to morphology and apoptosis...
  98. ncbi Association between HIV Type 1-specific T cell responses and CD4+ T cell counts or CD4+:CD8+ T cell ratios in HIV Type 1 subtype B infection in China
    Shaoyang Wang
    Department of Infectious Diseases, Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi an 710038, Peoples Republic of China
    AIDS Res Hum Retroviruses 22:780-7. 2006
    ....
  99. ncbi Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 78:1003-10. 2006
    ..It also uncovers the presence of a p24 reactivity, whose identity remains to be determined, in a significant fraction of samples with undetectable HIV-1 RNA under long-term HAART...
  100. ncbi Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses
    D W Notermans
    Division of Infectious Diseases, Tropical Medicine, and AIDS, AMC, 1105 AZ, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 17:1003-8. 2001
    ..The weakening of antiviral immunity with therapy may be relevant for current attempts to gain immunological control over the virus through structured treatment interruptions or therapeutic vaccinations...
  101. pmc Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference
    Wee Sung Park
    Department of Industrial Chemistry, Faculty of Engineering, Chiba Institute of Technology, 2 17 1 Tsudanuma, Narashino shi, Chiba 275 0016, Japan
    Nucleic Acids Res 30:4830-5. 2002
    ..The dsRNA interference method seems to be a promising new strategy for anti-HIV-1 gene therapeutics...

Research Grants54

  1. Transgenic/SCID-hu Mouse Model to Study HIV Therapeutics
    Harris Goldstein; Fiscal Year: 2005
    ..We will also examine the efficacy of Env-directed toxin-treatment to eliminate reservoirs of HIV-1-infected cells using our well-established thy/liv- SCID-hu mouse system. ..
  2. Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine
    Madhavan P Nair; Fiscal Year: 2010
    ....
  3. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
    ..The proposed ACTU will not only enroll patients into ACTG clinical trials, but will provide the ACTG the ability to address important questions concerning AIDS treatment and pathogenesis. ..
  4. Viral-induced placental impairment
    Samuel Parry; Fiscal Year: 2006
    ..These experiments will provide insights into the role of viral infection in the pathogenesis of placental dysfunction. ..
  5. Rational Design of CCR5 Antagonists as Anti-HIV-1 Drugs
    Asim Debnath; Fiscal Year: 2006
    ..The long term goal is to optimize the lead compounds through chemical syntheses and structure activity relationship (SAR) analyses and select the 3-4 best compounds for further preclinical studies. ..
  6. Stampidine: A Novel Broad-Spectrum Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of STAMP in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  7. Phase II SBIR: WHI-07: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ....
  8. OPINIONS OF BLOOD DONATION: A U.S. POPULATION SURVEY
    George Schreiber; Fiscal Year: 2005
    ..Findings will be rapidly disseminated to the transfusion medical community and government agencies. ..
  9. AIDS encephalopathy and HIV disease: role of opioids
    Madhavan Nair; Fiscal Year: 2006
    ..abstract_text> ..
  10. B-Synuclein as a Treatment for Lewy Body Disease
    Eliezer Masliah; Fiscal Year: 2005
    ..abstract_text> ..
  11. 10th-12th Conferences: Drug Abuse/Immunomodulation/AIDS
    Thomas Rogers; Fiscal Year: 2005
    ..The combination of the web site, and a brochure mailing should guarantee wide dissemination of information regarding the meeting, and guarantee publicity for the published results. ..
  12. Cell mediated Immunity to HCV in HIV+ Persons
    Arthur Kim; Fiscal Year: 2007
    ..This plan will be implemented under the supervision of Dr. Bruce Walker, and will involve bench research, data analysis, and didactic learning. [unreadable] [unreadable]..
  13. Vanadocenes as a New Class of Spermicidal Drugs
    OSMOND D CRUZ; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  14. CNS Viral Dynamics and Cellular Immunity During AIDS
    David Haas; Fiscal Year: 2009
    ..Characterizing these relationships will expand our knowledge regarding key events that lead to AIDS dementia, and may suggest novel approaches to other immunologic or viral-mediated diseases that affect the brain. ..
  15. Iron supplementation in HIV-infected pregnant women
    Victor Mwapasa; Fiscal Year: 2009
    ....
  16. Clinical Algorithms to Monitor HIV Treatment in Uganda
    Lisa Spacek; Fiscal Year: 2008
    ..Richard Moore and HIV laboratory science with Dr. Thomas Quinn. My long-term goal is to become an independent investigator of HIV clinical epidemiology in resource-limited settings. ..
  17. NATIONAL GENE VECTOR LABORATORY AT INDIANA UNIVERSITY
    Kenneth Cornetta; Fiscal Year: 2007
    ..abstract_text> ..
  18. DYNORPHIN AND GLIAL CELL IMMUNOMODULATION
    PHILLIP PETERSON; Fiscal Year: 2008
    ....
  19. HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS
    Madhavan Nair; Fiscal Year: 2005
    ..Further studies will elucidate the molecular mechanisms underlying the immuno- and neuropathogenic effects of heroin use in HIV-l infection, and may yield novel therapies for the treatment of heroin using, HIV-infected patients. ..
  20. MODULATION OF CELL-MEDIATED IMMUNE FUNCTION BY OPIATES
    PHILLIP PETERSON; Fiscal Year: 2007
    ..abstract_text> ..
  21. HIV INFECTION AND OPIOID-INDUCED IMMUNOREGULATION
    Thomas Rogers; Fiscal Year: 2007
    ..We expect the proposed studies will enhance our understanding of the role of opioid drugs of abuse in the interaction of the immune system with HIV. ..
  22. IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION
    Elizabeth Connick; Fiscal Year: 2007
    ..abstract_text> ..
  23. CYTOREDUCTIVE CHEMOTHERAPY TARGETING HIV RESERVOIRS
    Christopher Pilcher; Fiscal Year: 2004
    ..the PI with supervised laboratory experiences and didactic training in addition to a closely supervised clinical research experience, leading to R01 submission and establishment of the PI as an independent investigator ..
  24. FLP-102: Rationally Engineered Antiviral Protein
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
  25. DRUG RELATED CNS DAMAGE-SYNERGY WITH EFFECTS OF HIV
    Jeanne Bell; Fiscal Year: 2002
    ..Identification of particularly hazardous patterns of illicit drug(s) use, and of possible genetic susceptibility, could lead to more focused prevention and intervention strategies in at risk cohorts and individuals. ..
  26. ROLE OF MULTIDRUG RESISTANCE MUTATION IN HIV FITNESS
    Prem Sharma; Fiscal Year: 2002
    ....
  27. CD8+TCell Antiretroviral Mechanisms in Lymphoid Tissue
    Elizabeth Connick; Fiscal Year: 2003
    ..These studies could provide important insight into the immunopathogenesis of HIV-1 infection and suggest alternative targets for immune therapies. ..
  28. HIV 1 RECOMBINANTS TRANSMITTED PERINATALLY
    Boris Renjifo; Fiscal Year: 2002
    ..This study may provide information that will eventually be useful for decreasing rates of perinatal infection. ..
  29. ENHANCING THE INTRACELLULAR FUNCTIONING OF HIV RIBOZYMES
    John Rossi; Fiscal Year: 2001
    ..The results from this program will greatly facilitate the effective use of ribozyme treatment for HIV-1 infection in a gene therapy setting. ..
  30. HIGH AFFINITY AGONISTS OF HIV1 DEPENDENT FUSION
    Sylvie Blondelle; Fiscal Year: 2001
    ..Furthermore, studies toward the understanding of the mechanisms of action of these antagonists will be initiated. ..
  31. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 2001
    ..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
  32. NEURODEGENERATION IN HIV INFECTED DRUG USERS
    Jeanne Bell; Fiscal Year: 2003
    ..Elucidation of the interaction between drugs and HIV infection of the CNS could lead to more focused strategies to prevent cognitive decline in drug users, particularly those who are also HIV infected. ..
  33. TRANSGENIC MICE--MODEL FOR STUDYING HIV INFECTION OF THE
    Harris Goldstein; Fiscal Year: 2003
    ..These in vivo studies will be performed using novel transgenic mouse models that we have recently developed that display productive HIV-1 infection. ..
  34. The Role of CD8 on CD4+ T Cells
    Scott Kitchen; Fiscal Year: 2004
    ..These studies combined will allow us to determine the possible effects that the appearance or loss of this subset may have on HIV disease progression and antiviral immunity. ..
  35. HIV-1 Incidence and Genetic Diversity in the Caribbean
    William Blattner; Fiscal Year: 2004
    ....
  36. MID ATLANTIC PROSTATE CANCER BANK
    Jan Orenstein; Fiscal Year: 2004
    ..This resource will assure that investigators will obtain optimal research specimens with clinical-pathologic correlation for their studies. ..
  37. PHI-443: Novel Non-Spermicidal Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of PHI-443 in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  38. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
  39. BASIS OF SYNAPTIC PATHOLOGY IN ALZHEIMERS DISEASE
    Eliezer Masliah; Fiscal Year: 2001
    ..These studies will help to better understand the mechanisms of synaptic pathology in AD and to develop potential neuroprotective agents that will operate by enhancing the GT activity. ..
  40. HIV-1 entry inhibitors targeting Phe43 cavity in gp120
    Asim Debnath; Fiscal Year: 2003
    ..The long-term goal of this proposal is to optimize the lead compounds through chemical synthesis and structure activity analyses and select 3-4 best compounds for further preclinical studies as novel ianti-HIV-1 chemotherapeutic agents. ..
  41. Enhancing the efficacy of nucleoside analogs
    Arnon Lavie; Fiscal Year: 2009
    ..The long-term goal of this project is to develop methods to translate this Selective Enhanced Enzyme Delivery System (SEEDS) to applications for multiple types of malignancies. ..
  42. Impact of Alcohol Consumption on HIV/AIDS in Women
    William Blattner; Fiscal Year: 2005
    ..to-child transmission of HIV. ..
  43. Alphavirus Replicons for Mucosal HIV Vaccines
    Michael Vajdy; Fiscal Year: 2002
    ....
  44. STRUCTURAL BIOLOGY OF ENZYMES ACTIVATING PRODRUGS
    Arnon Lavie; Fiscal Year: 2008
    ..A long-term goal of this project is to engineer enzymes that possess improved prodrug activation efficiencies to be employed in antiviral and anticancer therapies. ..
  45. PHI 346: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Following successful completion of the Phase I in vivo efficacy studies, gel formulation of PHI-346 will be further explored as a vaginal dual-function microbicide in Phase II. ..
  46. Targeting Acute HIV
    Christopher Pilcher; Fiscal Year: 2007
    ..Perform detailed cost effectiveness modeling in order to optimize acute HIV-centered efforts at HIV prevention. ..
  47. DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1
    Mark Wainberg; Fiscal Year: 2001
    ..6. To determine whether these attenuated SIV constructs may protect against subsequent challenge with virulent forms of SIV and SIV/HIV hybrids. ..
  48. Design of Enzymes Mediating Anti-Cancer Drug Activation
    Arnon Lavie; Fiscal Year: 2005
    ..This Selective Enhanced Enzyme Delivery System (SEEDS) could be applicable in treating other malignancies using the appropriate antibodies, mutant enzymes and drugs...
  49. Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection
    Madhavan Nair; Fiscal Year: 2008
    ..These studies may lead to novel anti-HIV therapies such as targeting the CD4 independent, virus attachment receptor, DC-SIGN, or devising inhibitors of TDO and DC-SIGN or stimulating costimulatory molecules. ..
  50. COALITION FOR HIV VACCINE DEVELOPMENT
    William Blattner; Fiscal Year: 2006
    ..abstract_text> ..
  51. Mechanisms of Cocaine-Induced HIV-1 infection in NHA
    Jessica Reynolds; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  52. Mechanisms of in vivo protection from HIV infection
    Harris Goldstein; Fiscal Year: 2010
    ....
  53. OPIOIDS AND T CELL DIFFERENTIATION
    Thomas Rogers; Fiscal Year: 2001
    ..It is hoped that these studies will provide valuable information relating to the control of the T cell arm of the immune system in opioid abuse. ..